Summary:
- Teva Pharmaceutical Industries and Royalty Pharma have entered into an agreement to accelerate the development of a potential treatment for vitiligo, a skin condition that causes the loss of pigment in certain areas of the skin.
- The agreement will provide Teva with additional funding and resources to advance the clinical development of the treatment, which is currently in the early stages of testing.
- Vitiligo is a chronic, autoimmune condition that can have a significant impact on a person's quality of life, and there is a need for more effective treatments. The collaboration between Teva and Royalty Pharma aims to bring a new treatment option to patients as quickly as possible.